- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards | 4 | GlobeNewswire (USA) | ||
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 207 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 263 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 12.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events | 2 | GlobeNewswire (USA) | ||
| 27.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | 1 | GlobeNewswire (USA) | ||
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.02. | Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans | 1 | Benzinga.com | ||
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 851 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 05.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Welcomes New Members of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 02.02. | Micro-cap Polaryx Therapeutics to trade on the Nasdaq today via direct listing | 2 | Renaissance Capital | ||
| 02.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" | 308 | GlobeNewswire (Europe) | PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 30.01. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq | 261 | GlobeNewswire (Europe) | PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 27.01. | Polaryx Therapeutics, Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 27.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,310 | +18,56 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| IMMUNOVANT | 33,930 | +29,06 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| EVOTEC | 5,080 | +3,67 % | Aktien im Fokus - Deutsche Telekom: Jetzt oder nie - DEFAMA, Evotec, SFC Energy, Valneva und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,760 | +12,05 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| PRAXIS PRECISION MEDICINES | 348,62 | +8,74 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| HCW BIOLOGICS | 2,790 | +163,21 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,650 | -2,37 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ERASCA | 11,620 | +12,60 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,725 | +4,72 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,900 | +7,88 % | Tango Therapeutics Shares Fall 17% | ||
| CG ONCOLOGY | 64,69 | +2,20 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,470 | +9,74 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | - 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,105 | +8,95 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| BEAM THERAPEUTICS | 27,650 | +5,01 % | Beam Therapeutics presents AATD gene therapy trial data at ATS |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,950 Euro und damit +16,86 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.